Affinity Asset Advisors LLC recently announced the acquisition of new stake in Vincerx Pharma Inc. (NASDAQ:VINC). The institutional investor has increased its shareholding in the Healthcare company by 8.64% to 1.49 million shares with purchase of 0.12 million shares. This fresh investment now brings its stake to 7.05% valued currently at $1.52 million. In addition, Rock Springs Capital Management L raised its holdings by 0.29 million to 1.11 million shares. And Sabby Management LLC has lifted its position by 1.00% or 5000.0 shares – to 0.51 million shares.
With over 0.26 million Vincerx Pharma Inc. (VINC) shares trading Tuesday and a closing price of $1.32 on the day, the dollar volume was approximately $0.34 million. The shares have shown a negative half year performance of -11.41% and its price on 01/24/23 gained nearly 21.10%. Currently, there are 21.08M common shares owned by the public and among those 15.14M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for VINC have a consensus price objective of $5.75. The analysts have set the share’s price value over the next 12 months at a high of $10.00 and a low of $3.00. The average price target is 84.65% above its recent price level and an upside to the estimated low will see the stock gain 56.0% over that period. But an upside of 86.8% will see the stock hit the forecast high price target while median target price for the stock is $5.00.
Insiders at the company have transacted a total of 8 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 180,218 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Vincerx Pharma Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.33 million shares of the company’s stock, all valued at over $0.34 million. Vanguard Extended Market Index Fu bought 313.0 shares to see its total holdings expand to 0.17 million shares valued at over $0.18 million and representing 0.82% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.36% of the shares outstanding.
Shares of Vincerx Pharma Inc. (NASDAQ: VINC) opened at $1.12, up $0.03 from a prior closing price of $1.09. However, the script later moved the day high at 1.3400, up 21.10%. The company’s stock has a 5-day price change of 23.36% and 22.22% over the past three months. VINC shares are trading 29.41% year to date (YTD), with the 12-month market performance down to -81.01% lower. It has a 12-month low price of $0.63 and touched a high of $8.03 over the same period. VINC has an average intraday trading volume of 234.17K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 29.60%, 51.68%, and -9.58% respectively.
Institutional ownership of Vincerx Pharma Inc. (NASDAQ: VINC) shares accounts for 64.60% of the company’s 21.08M shares outstanding. Mutual fund holders own 30.38%, while other institutional holders and individual stakeholders account for 60.00% and 3.55% respectively.
It has a market capitalization of $27.39M. The earnings-per-share (ttm) stands at -$2.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.97% over the week and 11.56% over the month.
Analysts forecast that Vincerx Pharma Inc. (VINC) will achieve an EPS of -$0.55 for the current quarter, -$0.47 for the next quarter and -$2.07 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.8 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$1.39 a year ago. Earnings per share for the fiscal year are expected to increase by 27.70%, and 25.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Vincerx Pharma Inc. (VINC) as a “Strong Buy” at a consensus score of 1.80. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the VINC, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 14, 2022, with the firm’s price target at $25. Cantor Fitzgerald coverage for the Vincerx Pharma Inc. (VINC) stock in a research note released on December 23, 2021 offered a Overweight rating with a price target of $25. SVB Leerink was of a view on November 01, 2021 that the stock is Outperform, while Laidlaw gave the stock Buy rating on September 13, 2021, issuing a price target of $30. B. Riley Securities on their part issued Buy rating on August 25, 2021.